Introduction
Advances in precision medicine have transformed the treatment of non-small cell lung cancer (NSCLC), allowing healthcare providers to match certain targeted therapies with specific genetic changes found in a patient’s tumor. For people whose lung cancer tests positive for a ROS1 rearrangement, targeted treatment may provide an effective option designed to address the underlying driver of the disease.
Ibtrozi is a prescription targeted therapy approved for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. By selectively blocking the abnormal ROS1 protein, Ibtrozi helps interrupt signals that promote cancer cell growth and survival. It is approved for eligible patients regardless of whether they have previously received a ROS1 tyrosine kinase inhibitor, provided their tumor tests positive using an FDA-approved diagnostic test.
As a specialty oncology medication, Ibtrozi can be expensive without adequate insurance coverage or financial assistance. Many patients researching the Ibtrozi patient assistance program are looking for ways to reduce out-of-pocket medication costs while maintaining access to treatment.
Prescription Hope offers qualified patients access to affordable brand-name medications through patient assistance programs.
What Is the Ibtrozi Patient Assistance Program?
Understanding Ibtrozi Prescription Assistance
When patients deal with serious conditions such as NSCLC, they often require specialty medications. For instance, some patients are prescribed Ibtrozi.
Unfortunately, Ibtrozi can be extremely expensive. Many Americans cannot afford it and search for affordable Ibtrozi or Ibtorzi savings programs.
In general, pharmaceutical manufacturers understand that some of their brand-name medications are too expensive for Americans to afford out of pocket.
To help ease the financial burden, manufacturers often launch patient assistance programs, such as the Ibtrozi patient assistance program.
However, some patient assistance programs have been known to include complex application processes. Patients report feeling frustrated, and some even give up trying to apply.
Prescription Hope offers another way.
How Expert Advocates Help Make Ibtrozi More Affordable
Personalized Medication Assistance
Prescription Hope offers Ibtrozi enrollment assistance for qualified patients. Our prescription assistance specialists provide patient support services for those looking to apply for patient assistance programs.
Our team of patient advocates handles form completion, document and signature collection, communicating with healthcare providers and manufacturers, and more.
Ongoing Patient Support
When needing specialty oncology support, patients trust Prescription Hope with their long-term medication assistance. Our team continues to manage the administrative tasks required for program enrollment. Such tasks include document and form updates, refill scheduling, yearly renewals, issue resolution, and more.
Navigating Lung Cancer Treatment Costs
While some may believe that Ibtrozi cost assistance still comes with a high price tag, the truth is Prescription Hope’s service rate is a clear and low $70.00 per month, per medication.
All services Prescription Hope provides are included in this low monthly rate, and patients enjoy knowing they won’t be hit with hidden fees, add-on charges, or medication costs.
And if we can’t help you save on your medication costs, then you pay nothing!
Ibtrozi Patient Assistance Eligibility
General Eligibility Requirements
If you’ve been wondering about Ibtrozi eligibility and need to know who qualifies for Ibtrozi assistance, be sure to enroll with Prescription Hope to find out.
All patient assistance programs hold strict requirements for qualification, and each program’s criteria differ, but all use some of the same general categories. Those include:
Income: All programs use income threshold as a requirement category. Each one’s threshold is different.
Insurance: All programs also use insurance coverage status as a requirement category. However, each program maintains its own specific criteria.
Prescription: Patients must have a valid prescription for the brand-name medication they are enrolling for.
U.S. Residency: All patients must be a legal U.S. resident to qualify.
Simple Enrollment With Expert Support
Getting Started With Enrollment
If you’re ready to enroll in Ibtrozi assistance, then enroll with Prescription Hope today. Our process is only 6 simple steps:
- Submit Information: Fill out our enrollment form in only a few minutes.
- Advocate Contact: Once your enrollment form is submitted, a patient advocate will reach out within 1-2 business days.
- Document Collection: After a quick prequalification, our team will collect all needed documents.
- Provider Coordination: We also collect all necessary signatures.
- Program Submission: Once we have everything we need, we submit your application on your behalf and coordinate with the manufacturer throughout the process.
- Medication Delivery: After approval, qualified patients typically receive their medication within 2 weeks. All medications ship directly from the manufacturer to their home or doctor’s office.
Understanding Ibtrozi
How Ibtrozi Works
Ibtrozi is a tyrosine kinase inhibitor (TKI) that selectively targets ROS1, an abnormal protein produced when the ROS1 gene becomes rearranged in certain non-small cell lung cancers. These ROS1 rearrangements create continuous growth signals that allow cancer cells to multiply and survive.
By blocking ROS1 activity, Ibtrozi interrupts these abnormal signaling pathways, helping slow or stop cancer cell growth and potentially shrink tumors in eligible patients. Because the medication specifically targets tumors with ROS1 rearrangements, treatment is appropriate only for patients whose cancer tests positive using an FDA-approved diagnostic test.
Ibtrozi has demonstrated activity in both patients who have not previously received a ROS1 tyrosine kinase inhibitor and those who have already been treated with ROS1-targeted therapy, providing an additional treatment option across different stages of care.
What Conditions Does Ibtrozi Treat?
Ibtrozi is FDA-approved for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Patients should be selected for treatment based on confirmation of a ROS1-positive tumor using an FDA-approved test. The medication is approved regardless of prior treatment with a ROS1 tyrosine kinase inhibitor, including patients who are TKI-naïve and those previously treated with a ROS1-targeted therapy.
ROS1-positive NSCLC is a subtype of lung cancer driven by a specific genetic alteration. Identifying this mutation through biomarker testing allows healthcare providers to select targeted therapies such as Ibtrozi that are designed specifically for tumors carrying the ROS1 rearrangement.
Benefits of Treatment
Ibtrozi provides a targeted treatment option for patients with ROS1-positive non-small cell lung cancer by addressing one of the genetic drivers responsible for cancer growth. Rather than acting as traditional chemotherapy, the medication selectively blocks abnormal ROS1 signaling involved in tumor development.
Potential benefits include shrinking tumors, slowing the progression of advanced lung cancer, providing a targeted treatment based on tumor genetics, demonstrating activity in patients with or without prior ROS1-targeted therapy, and showing intracranial (brain) antitumor activity in clinical studies. As a once-daily oral medication, Ibtrozi also offers the convenience of at-home treatment for eligible patients.
Treatment outcomes vary among individuals. Healthcare providers routinely monitor treatment response, disease progression, and side effects throughout therapy to determine whether treatment should continue or require dose adjustments.
Important Safety Information and Side Effects
Ibtrozi does not carry an FDA Boxed Warning.
The most commonly reported side effects include diarrhea, constipation, nausea, vomiting, fatigue, dizziness, rash, decreased appetite, muscle pain (myalgia), increased liver enzyme levels, elevated uric acid levels, and increased creatine phosphokinase (CPK) levels. Patients should notify their healthcare provider if side effects become severe, persistent, or difficult to manage.
Ibtrozi may cause hepatotoxicity (liver injury). Healthcare providers should monitor liver function before treatment begins and throughout therapy. Patients should promptly report symptoms such as yellowing of the skin or eyes, dark urine, persistent nausea or vomiting, or severe fatigue.
Serious or life-threatening interstitial lung disease (ILD) or pneumonitis has occurred during treatment. Patients should immediately report new or worsening cough, shortness of breath, difficulty breathing, or fever. Depending on the severity of symptoms, treatment may need to be interrupted or permanently discontinued.
Ibtrozi may prolong the QT interval, increasing the risk of serious heart rhythm abnormalities. Healthcare providers may monitor electrocardiograms (ECGs) and electrolyte levels in patients who have risk factors for QT prolongation or who take medications known to affect the QT interval.
Treatment may also increase uric acid levels (hyperuricemia), which can contribute to gout or other complications. Periodic blood tests may be performed to monitor uric acid during treatment.
Some patients experience muscle pain accompanied by elevated creatine phosphokinase (CPK) levels. Patients should promptly report unexplained muscle pain, weakness, or tenderness to their healthcare provider.
Skeletal fractures have been reported during treatment. Patients should notify their healthcare provider if they develop new bone pain or experience injuries that may suggest a fracture.
Based on its mechanism of action, Ibtrozi may cause fetal harm if used during pregnancy. Females who can become pregnant should use effective contraception during treatment and for the recommended period after the final dose. Male patients with partners who can become pregnant should also follow contraceptive recommendations. Patients should avoid breastfeeding during treatment and for the period recommended in the prescribing information after the final dose.
Ibtrozi may interact with strong or moderate CYP3A inhibitors, strong or moderate CYP3A inducers, and medications known to prolong the QT interval. Patients should provide their healthcare provider with a complete list of prescription medications, over-the-counter medicines, vitamins, and herbal supplements before starting treatment.
Ibtrozi is taken orally as 600 mg (three 200 mg capsules) once daily on an empty stomach. Patients should not eat for at least two hours before and two hours after taking each dose. Capsules should be swallowed whole. If a dose is missed or vomiting occurs after taking a dose, patients should follow the prescribing information or their healthcare provider’s instructions rather than taking an extra dose. Treatment generally continues until disease progression or unacceptable toxicity occurs.
Healthcare providers typically monitor liver function, electrocardiograms, and electrolytes when appropriate, uric acid levels, creatine phosphokinase (CPK), pulmonary symptoms suggestive of ILD or pneumonitis, and overall treatment response throughout therapy.
Access to Multiple Medications
Support Beyond Ibtrozi
Those who need specialty medication access for several medications may benefit from Prescription Hope’s ability to access multiple medication assistance programs on behalf of our patients.
With a list of hundreds of accessible brand-name medications, our team of patient advocates can provide support for many medications at once. Whether you qualify for one or several, we can help.
All for $70.00 per month, per medication.
Why Choose Prescription Hope for Ibtrozi Assistance
Patient-Focused Medication Support
For 20 years, Prescription Hope has provided advocacy and support on behalf of patients looking to lower their medication costs by accessing patient assistance programs. Getting Ibtrozi assistance through Prescription Hope is as simple as $70.00 per month, per medication for qualified patients.
Simplified Access to Specialty Therapies
Our $70.00 per month, per medication offers clients freedom from the burden of high medication costs. Plus, we never charge hidden fees, add-ons, or medication costs.
Ongoing Prescription Assistance
Prescription Hope doesn’t just offer long-term medication support, but takes care of the administrative tasks associated with enrollment in a patient assistance program. Our team of patient advocates handles form updates, document and signature collection, issue resolution, and more.
If you’re looking to avoid the bureaucracy and red tape associated with many patient assistance programs, then be sure to enroll with Prescription Hope today!